Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report report published on Friday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently commented on VNDA. HC Wainwright assumed coverage on Vanda Pharmaceuticals in a report on Thursday, October 31st. They set a “buy” rating and a $18.00 target price for the company. Cantor Fitzgerald lifted their target price on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st.

Vanda Pharmaceuticals Trading Up 4.1 %

Shares of Vanda Pharmaceuticals stock opened at $4.85 on Friday. The stock’s fifty day moving average price is $4.81 and its 200-day moving average price is $5.24. Vanda Pharmaceuticals has a 12 month low of $3.30 and a 12 month high of $6.75. The firm has a market cap of $282.71 million, a P/E ratio of -25.53 and a beta of 0.77.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Nantahala Capital Management LLC lifted its stake in Vanda Pharmaceuticals by 57.3% during the second quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company’s stock worth $9,003,000 after purchasing an additional 580,265 shares during the last quarter. Profit Investment Management LLC lifted its stake in Vanda Pharmaceuticals by 159.3% during the second quarter. Profit Investment Management LLC now owns 571,324 shares of the biopharmaceutical company’s stock worth $3,228,000 after purchasing an additional 351,000 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Vanda Pharmaceuticals by 17.0% during the second quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock worth $11,379,000 after purchasing an additional 292,172 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Vanda Pharmaceuticals during the first quarter worth approximately $1,158,000. Finally, Monaco Asset Management SAM purchased a new stake in Vanda Pharmaceuticals during the second quarter worth approximately $1,090,000. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.